Larry Alphs

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. ncbi request reprint How study designs influence comparative effectiveness outcomes: the case of oral versus long-acting injectable antipsychotic treatments for schizophrenia
    Larry Alphs
    Janssen Scientific Affairs, LLC, 1125 Trenton Harbourton Road, Titusville, NJ, USA Electronic address
    Schizophr Res 156:228-32. 2014
  2. pmc Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
    Larry Alphs
    CNS Medical Affairs, LLC, Titusville, NJ, USA
    Neuropsychiatr Dis Treat 9:341-50. 2013
  3. ncbi request reprint Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia
    Larry Alphs
    Therapeutic Area Leader Psychiatry, Janssen Scientific Affairs, LLC, 1125 Trenton Harbourton Road A32404, Titusville, NJ 08560, USA 1 609 730 3693 1 609 730 3125
    Expert Opin Pharmacother 15:1029-42. 2014
  4. ncbi request reprint Limited utility of number needed to treat and the polarity index for bipolar disorder to characterize treatment response
    Larry Alphs
    Janssen Scientific Affairs, LLC, 1125 Trenton Harbourton Road, Titusville, NJ 08560 2000, USA Electronic address
    Eur Neuropsychopharmacol 23:1597-9. 2013
  5. pmc Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?
    Larry Alphs
    Janssen Scientific Affairs, LLC, Titusville, NJ, USA
    Int J Neuropsychopharmacol 15:1003-14. 2012
  6. pmc Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial
    Larry Alphs
    Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA
    Ann Gen Psychiatry 10:12. 2011
  7. pmc Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases
    Larry Alphs
    Ortho McNeil Janssen Scientific Affairs, 1125 Trenton Harbourton Road, Titusville, NJ 08560, USA
    Curr Drug Saf 6:43-5. 2011
  8. doi request reprint Relationship between the clinical global impression of severity for schizoaffective disorder scale and established mood scales for mania and depression
    Ibrahim Turkoz
    Janssen Research and Development, LLC, 1125 Trenton Harbourton Road, Titusville, NJ 08650, USA
    J Affect Disord 150:17-22. 2013
  9. ncbi request reprint Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison
    Dong Jing Fu
    aMedical Affairs bMedical Information, Janssen Scientific Affairs, LLC cBiostatistics, B and P, Janssen Research and Development, LLC, Titusville, New Jersey, USA
    Int Clin Psychopharmacol 29:45-55. 2014
  10. pmc Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms
    Wayne Macfadden
    Janssen Scientific Affairs, LLC, Titusville, NJ, USA
    BMC Psychiatry 11:171. 2011

Detail Information

Publications25

  1. ncbi request reprint How study designs influence comparative effectiveness outcomes: the case of oral versus long-acting injectable antipsychotic treatments for schizophrenia
    Larry Alphs
    Janssen Scientific Affairs, LLC, 1125 Trenton Harbourton Road, Titusville, NJ, USA Electronic address
    Schizophr Res 156:228-32. 2014
    ..This paper reviews the relative impact of these features when comparing LAI and oral antipsychotic treatments and makes recommendations for improving these comparative designs. ..
  2. pmc Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
    Larry Alphs
    CNS Medical Affairs, LLC, Titusville, NJ, USA
    Neuropsychiatr Dis Treat 9:341-50. 2013
    ....
  3. ncbi request reprint Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia
    Larry Alphs
    Therapeutic Area Leader Psychiatry, Janssen Scientific Affairs, LLC, 1125 Trenton Harbourton Road A32404, Titusville, NJ 08560, USA 1 609 730 3693 1 609 730 3125
    Expert Opin Pharmacother 15:1029-42. 2014
    ..As patients with schizophrenia frequently present with diverse and challenging symptoms, it is important to understand the effects of antipsychotics in treating these different symptom subgroups and the timing of these responses...
  4. ncbi request reprint Limited utility of number needed to treat and the polarity index for bipolar disorder to characterize treatment response
    Larry Alphs
    Janssen Scientific Affairs, LLC, 1125 Trenton Harbourton Road, Titusville, NJ 08560 2000, USA Electronic address
    Eur Neuropsychopharmacol 23:1597-9. 2013
    ..This commentary identifies some of the specific limitations of the NNT and PI constructs when applied to treatments of bipolar disorder. ..
  5. pmc Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?
    Larry Alphs
    Janssen Scientific Affairs, LLC, Titusville, NJ, USA
    Int J Neuropsychopharmacol 15:1003-14. 2012
    ..This is followed by a description of protocol/study design and study conduct issues that are contributing to a growing placebo effect in clinical trials. Potential solutions to these problems are provided...
  6. pmc Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial
    Larry Alphs
    Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA
    Ann Gen Psychiatry 10:12. 2011
    ..abstract:..
  7. pmc Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases
    Larry Alphs
    Ortho McNeil Janssen Scientific Affairs, 1125 Trenton Harbourton Road, Titusville, NJ 08560, USA
    Curr Drug Saf 6:43-5. 2011
    ..Examination of these prospective databases finds no evidence that risperidone LAI and paliperidone palmitate are associated with PDSS and suggest that findings seen with another antipsychotic LAI are not generalizable...
  8. doi request reprint Relationship between the clinical global impression of severity for schizoaffective disorder scale and established mood scales for mania and depression
    Ibrahim Turkoz
    Janssen Research and Development, LLC, 1125 Trenton Harbourton Road, Titusville, NJ 08650, USA
    J Affect Disord 150:17-22. 2013
    ..This analysis explored the relationship between ratings on HAM-D-17 or YMRS and those on the depressive or manic subscale of CGI-S for schizoaffective disorder (CGI-S-SCA)...
  9. ncbi request reprint Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison
    Dong Jing Fu
    aMedical Affairs bMedical Information, Janssen Scientific Affairs, LLC cBiostatistics, B and P, Janssen Research and Development, LLC, Titusville, New Jersey, USA
    Int Clin Psychopharmacol 29:45-55. 2014
    ..In patients with recently diagnosed schizophrenia, the tolerability and efficacy of PP and RLAI were generally similar over 13 weeks...
  10. pmc Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms
    Wayne Macfadden
    Janssen Scientific Affairs, LLC, Titusville, NJ, USA
    BMC Psychiatry 11:171. 2011
    ....
  11. doi request reprint Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone
    Jennifer Kern Sliwa
    Janssen Scientific Affairs, LLC, 1125 Trenton Harbourton Road, Titusville, NJ, USA
    Schizophr Res 132:28-34. 2011
    ..To examine efficacy and safety of acute treatment with paliperidone palmitate in subjects with schizophrenia whose disease remained symptomatic despite recent treatment with oral risperidone...
  12. pmc Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial
    Cynthia A Bossie
    Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA
    BMC Psychiatry 11:79. 2011
    ..These post-hoc analyses addressed two commonly encountered clinical issues regarding the initiation dosing: the time to onset of efficacy and the associated tolerability...
  13. doi request reprint A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently
    Wayne Macfadden
    Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, NJ 08560, USA
    Bipolar Disord 11:827-39. 2009
    ..This study assessed whether adjunctive maintenance treatment with risperidone long-acting therapy (RLAT), added to treatment-as-usual (TAU) medications for bipolar disorder, delays relapse in patients with bipolar disorder type I...
  14. doi request reprint Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone
    Carla M Canuso
    Ortho McNeil Janssen Scientific Affairs, LLC, 1125 Trenton Harbourton Road A32404, Titusville, NJ 08560, USA
    Int Clin Psychopharmacol 25:155-64. 2010
    ..1%), constipation (7.6%), headache (7.6%) and somnolence (6.6%). Participants with schizophrenia who were suboptimally responsive to risperidone reported improved medication satisfaction after initiation of paliperidone ER...
  15. pmc Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose
    Mahesh N Samtani
    Janssen Research and Development, LLC, NJ, USA
    Neuropsychiatr Dis Treat 9:721-30. 2013
    ..Recently, expansion of the day 8 dosing window from ±2 to ±4 days has been approved in the United States based on results obtained from the model-based simulations and review of safety data presented here...
  16. doi request reprint Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorder
    Gahan Pandina
    Janssen Research and Development, LLC, Titusville, NJ, USA
    Schizophr Res 143:312-8. 2013
    ..This study explored the relationships among cognitive functioning, clinical symptoms, overall functionality, and demographic characteristics...
  17. doi request reprint Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data
    Mahesh N Samtani
    Johnson Johnson Pharmaceutical Research Development, L L C, Raritan, NJ, USA
    CNS Drugs 25:829-45. 2011
    ..Population PK modelling presented in this review has helped provide practical guidance for administering this novel LAI antipsychotic...
  18. doi request reprint Clinical characteristics and resource utilization of patients with bipolar disorder who have frequent psychiatric interventions
    J Thomas Haskins
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Titusville, NJ 08560 0200, USA
    J Med Econ 13:552-8. 2010
    ....
  19. pmc Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate
    Jennifer Kern Sliwa
    Janssen Scientific Affairs, LLC, NJ, USA
    BMC Psychiatry 14:52. 2014
    ..We explored the relationship between body mass index (BMI) and metabolic events in patients with schizophrenia receiving long-acting injectable paliperidone palmitate (PP) in a long-term trial...
  20. pmc Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
    Jennifer Kern Sliwa
    Janssen Scientific Affairs LLC, Titusville, NJ, USA
    Neuropsychiatr Dis Treat 8:375-85. 2012
    ....
  21. pmc Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalization
    Michael Markowitz
    Janssen Scientific Affairs, LLC, Titusville, New Jersey
    BMC Psychiatry 13:246. 2013
    ..e., before and after schizophrenia-related hospitalization) among Medicaid-enrolled patients experiencing a schizophrenia-related hospitalization...
  22. pmc Management of antipsychotic treatment discontinuation and interruptions using model-based simulations
    Mahesh N Samtani
    Janssen Research and Development, Raritan, NJ, USA
    Clin Pharmacol 4:25-40. 2012
    ..These pharmacokinetic model-based simulations analyze predicted antipsychotic plasma concentrations in nonadherence and treatment interruption scenarios and with treatment reinitiation...
  23. pmc A Prospective Study Comparing the Long-term Effectiveness of Injectable Risperidone Long-acting Therapy and Oral Aripiprazole in Patients with Schizophrenia
    Wayne Macfadden
    Dr Macfadden was with Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, New Jersey, at the time of this analysis Dr Macfadden currently is Medical Director at Princeton Medical Institute, Princeton, New Jersey Drs Ma and Haskins are with Johnson and Johnson Pharmaceutical Research and Development, LLC, Titusville, New Jersey and Drs Bossie and Alphs are with Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, New Jersey
    Psychiatry (Edgmont) 7:23-31. 2010
    ....
  24. pmc Comparison of the Peak-to-trough Fluctuation in Plasma Concentration of Long-acting Injectable Antipsychotics and Their Oral Equivalents
    John J Sheehan
    Dr Sheehan was an employee of Janssen Scientific Affairs, LLC, Titusville, New Jersey, at the time of this analysis and is currently an employee of Bristol Myers Squibb, Plainsboro, New Jersey Drs Reilly, FU, and Alphs are employees of Janssen Scientific Affairs, LLC, Titusville, New Jersey
    Innov Clin Neurosci 9:17-23. 2012
    ..Further study is needed with more robust and generalizable peak-to-trough fluctuation data...
  25. ncbi request reprint Safety of paliperidone extended-release in patients with schizophrenia or schizoaffective disorder and hepatic disease
    Joan Amatniek
    Janssen Scientific Affairs, Bristol Myers Squibb, LLC, Titusville, NJ, Plainsboro, NJ, USA
    Clin Schizophr Relat Psychoses 8:8-20. 2014
    ..This multicenter, open-label, single-arm, crossover study evaluated the safety and efficacy of paliperidone extended-release (ER) in patients with schizophrenia or schizoaffective disorder and hepatic disease...